Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: a multicenter retrospective study.

Published: 11 August 2022| Version 1 | DOI: 10.17632/rjvr5dkmm7.1
Contributors:
Azael Freites-Martinez,
Vasiliki Nikolaou,
Konstantinos Lallas,
cristina carrera,
Pietro Sollena,
Zoe Apalla,
Davide Fattore,
Michela Starace,
Gabriella Fabbrocini,
Sonia Segura,
Julia Riganti,
Vincent Sibaud

Description

Supplemental Table 1. Clinical differences between acneiform rash, papulopustular rosacea, folliculitis, and hidradenitis suppurativa attributed to immune checkpoint inhibitors and differential diagnosis to consider in cancer patients Supplemental Table 2. Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0). Following the clinical features and distribution described for each case of follicular cirAE, the severity grading was obtained by oncodermatologists from the clinical description if not available by the grading CTCAEv5.0.

Files

Categories

Dermatology, Drug Adverse Reactions, Rosacea, Acne, Folliculitis, Immune Checkpoint Inhibitor

License